Gadobutrol (Gadavist, Gadovist, BAY86-4875)
Phase 3Completed 0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Central Nervous System Diseases
Conditions
Central Nervous System Diseases
Trial Timeline
Dec 1, 2007 → Dec 1, 2008
NCT ID
NCT00623467About Gadobutrol (Gadavist, Gadovist, BAY86-4875)
Gadobutrol (Gadavist, Gadovist, BAY86-4875) is a phase 3 stage product being developed by Bayer for Central Nervous System Diseases. The current trial status is completed. This product is registered under clinical trial identifier NCT00623467. Target conditions include Central Nervous System Diseases.
What happened to similar drugs?
4 of 19 similar drugs in Central Nervous System Diseases were approved
Approved (4) Terminated (2) Active (13)
Hype Score Breakdown
Clinical
17
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01890434 | Phase 3 | Completed |
| NCT01104584 | Phase 3 | Completed |
| NCT01067976 | Phase 3 | Completed |
| NCT00623467 | Phase 3 | Completed |
| NCT00468819 | Phase 1 | Completed |
Competing Products
20 competing products in Central Nervous System Diseases